Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
Physician's Weekly,
FRIDAY, Oct. 6, 2023 (HealthDay News) — The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is…
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
Overview of attention for article published in The Lancet, September 2023
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (98th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Mentioned by
- news
- 11 news outlets
- blogs
- 1 blog
- 17 X users
- patent
- 7 patents
- 2 Redditors
- guideline
- 1 clinical guideline source
- podcasts
- 2 podcasts
Readers on
- mendeley
- 74 Mendeley